Company profile: UBC
1.1 - Company Overview
Company description
- Provider of pharmaceutical support services for life science companies, including evidence development, safety and risk management, patient access, technology solutions, and clinical services. UBC leverages real-world data, technology, and analytics to enhance late-stage research, demonstrate safety, improve access and adherence, and speed therapy initiation.
Products and services
- Safety & Risk Management: Employs innovative technologies, automation-enabled workflows, and analytics insights to mitigate risk and demonstrate product safety across its lifecycle
- Evidence Development: Data-driven systems connecting real-world data, technology, and analytics to enhance strategy, study design, and late-stage research for informed decision-making
- Patient Access: Customizable components designed to improve patient access, affordability, and adherence by eliminating barriers and accelerating therapy initiation speed
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to UBC
Biose
HQ: France
Website
- Description: Provider of pharmaceuticals based on live bacteria, with 60 years of experience and specialized skills across discovery, process development, manufacturing, and registration, focused on health through microbiota and microbiome science.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biose company profile →
GL Chemtec
HQ: Canada
Website
- Description: Provider of custom small-molecule API discovery, process development, scale-up and manufacturing for life sciences; tailored biomedical polymers and hydrogels for drug delivery and medical devices (including silicone hydrogels, functionalized biopolymers, emulsions, synthetic organoids); integrated drug-delivery solutions combining small-molecule chemistry and polymer design; and analytical method development and transfer, stability studies and sample analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GL Chemtec company profile →
Cerbios
HQ: Switzerland
Website
- Description: Provider of chemical and biological active pharmaceutical ingredients (APIs), including high-potency APIs (HPAPIs) and antibody-drug conjugates (ADCs), with manufacturing and development capabilities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerbios company profile →
Q1 Scientific
HQ: Ireland
Website
- Description: Provider of environmentally controlled stability storage services for the pharmaceutical, medical device and life sciences industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q1 Scientific company profile →
PolyPeptide
HQ: Switzerland
Website
- Description: Provider of contract manufacturing for peptides and peptide-related molecules with a global presence ensuring reliable supply. One of the world's largest independent contract manufacturers of therapeutic peptides, offering peptide and oligonucleotide API development and manufacturing, generic and cosmetic peptides, and green chemistry initiatives, including a production-scale solvent recovery system with Donaldson Company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PolyPeptide company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for UBC
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to UBC
2.2 - Growth funds investing in similar companies to UBC
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for UBC
4.2 - Public trading comparable groups for UBC
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →